EGFR and neoplasm: Furthermore, replacement of anti-EGFR nanobody by anti-EGFR single-chain variable fragment (ESDRL) antibody domain did not result in therapeutic benefit compared with EVDRL treatment, suggesting that the specific combination of targeting cell proliferation and death pathways in tumor cells is essential.